Clinical Trials Logo

Concurrent Chemoradiotherapy clinical trials

View clinical trials related to Concurrent Chemoradiotherapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06288373 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Start date: March 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB(tumors >4 cm in diameter)will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.

NCT ID: NCT05944809 Not yet recruiting - Esophageal Cancer Clinical Trials

The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

The goal of this interventional study is to explore the protective effect of prophylactic TPO combined with bone marrow sparing (BMS)-IMRT in patients with esophageal cancer undergoing concurrent chemoradiotherapy. The main purpose is to reduce the incidence of all grades of thrombocytopenia from 35% to less than 10% by the intervention of study. Participants will initiate concurrent chemoradiotherapy within 2 weeks after enrollment,and they will receive subcutaneous injection of recombinant human thrombopoietin (rhTPO) 15000U once a week during the radiotherapy.

NCT ID: NCT05621707 Not yet recruiting - Immunotherapy Clinical Trials

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)

RICE
Start date: November 20, 2022
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer . The purpose of this study was to evaluate the efficacy and safety of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer.